Celsius Therapeutics appoints Sarah Grant as CMO

Celsius Therapeutics, a privately-held biotech developing precision medicines for cancer and autoimmune disease through single-cell RNA sequencing, has named Sarah Grant its chief medical officer (CMO).

She will lead the US company’s clinical strategy and development of its pipeline of therapies for autoimmune disease and cancer, including its potential first-in-class TREM1 antibody program for the treatment of inflammatory bowel disease, and the multiple ongoing drug discovery programs in oncology.

"Celsius has pioneered a new path to understand the cells that drive disease progression for heterogeneous diseases with complex disease biology"